星空传媒91传媒制片厂|明星换脸五级片|麻豆传媒映画女演员王茜|麻豆在传媒在线|九九国产|91制片厂在线观看一二区|夜夜草视频|四虎影院在线播放|国产精品亚洲国际在线看|大象传媒国产第一页,麻豆映画传媒有免费的吗,91制片厂安卓,亚洲成年人精选,91你懂得国产,爱豆视传媒短视频免费,免费一级片

The phase 3 study findings of the single-drug head-to-head clinical trial between Ivonescimab, the world's first approved bispecific antibody independently developed by Zhongshan-based company Akeso, and Pembrolizumab was published in The Lancet, one of the world's top medical journals.

The single-drug head-to-head trial directly compares the efficacy of two drugs under the same conditions through clinical trials. The study finding shows that, compared to Pembrolizumab, Ivonescimab significantly prolonged patients' progression-free survival and reduced the risk of disease progression or death by 49%. Ivonescimab is also the world's first drug to outperform Pembrolizumab in a phase 3 single-drug head-to-head trial.

Ivonescimab (trade name: 依達(dá)方?) was approved for market by China's National Medical Products Administration in May 2024 for the treatment of non-small cell lung cancer.

As a globally competitive biopharmaceutical company that has grown and has been rooted in Zhongshan's Torch Development Zone for over a decade, Akeso always focuses on the development of innovative antibody drugs.